Molecular Dynamics Simulations and Structure-Based Rational Design Lead to Allosteric HCV NS5B Polymerase Thumb Pocket 2 Inhibitor with Picomolar Cellular Replicon Potency

被引:25
|
作者
Hucke, Oliver [1 ]
Coulombe, Rene [1 ]
Bonneau, Pierre [1 ]
Bertrand-Laperle, Megan [1 ]
Brochu, Christian [1 ]
Gillard, James [1 ]
Joly, Marc-Andre [1 ]
Landry, Serge [1 ]
Lepage, Olivier [1 ]
Llinas-Brunet, Montse [1 ]
Pesant, Marc [1 ]
Poirier, Martin [1 ]
Poirier, Maude [1 ]
McKercher, Ginette [1 ]
Marquis, Martin [1 ]
Kukolj, George [1 ]
Beaulieu, Pierre L. [1 ]
Stammers, Timothy A. [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada
关键词
HEPATITIS-C-VIRUS; PALLADIUM-CATALYZED ARYLATION; DEPENDENT RNA-POLYMERASE; NS3 PROTEASE INHIBITOR; BI; 201335; CRYSTAL-STRUCTURE; FORCE-FIELD; INFECTION; DISCOVERY; EFFICACY;
D O I
10.1021/jm4004522
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design and preliminary SAR of a new series of 1H-quinazolin-4-one (QAZ) allosteric HCV NS5B thumb pocket 2 (TP-2) inhibitors was recently reported. To support optimization efforts, a molecular dynamics (MD) based modeling workflow was implemented, providing information on QAZ binding interactions with NS5B. This approach predicted a small but critical ligand-binding induced movement of a protein backbone region which increases the pocket size and improves access to the backbone carbonyl groups of Val 494 and Pro 495. This localized backbone shift was consistent with key SAR results and was subsequently confirmed by X-ray crystallography. The MD protocol guided the design of inhibitors, exploiting novel H-bond interactions with the two backbone carbonyl groups, leading to the first thumb pocket 2 NS5B inhibitor with picomolar antiviral potency in genotype (gt) 1a and 1b replicons (EC50 = 120 and 110 pM, respectively) and with EC50 <= 80 nM against gt 2-6.
引用
收藏
页码:1932 / 1943
页数:12
相关论文
共 33 条
  • [31] Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides
    de Vicente, Javier
    Hendricks, Robert T.
    Smith, David B.
    Fell, Jay B.
    Fischer, John
    Spencer, Stacey R.
    Stengel, Peter J.
    Mohr, Peter
    Robinson, John E.
    Blake, James F.
    Hilgenkamp, Ramona K.
    Yee, Calvin
    Adjabeng, George
    Elworthy, Todd R.
    Li, Jim
    Wang, Beihan
    Bamberg, Joe T.
    Harris, Seth F.
    Wong, April
    Leveque, Vincent J. P.
    Najera, Isabel
    Le Pogam, Sophie
    Rajyaguru, Sonal
    Ao-Ieong, Gloria
    Alexandrova, Ludmila
    Larrabee, Susan
    Brandl, Michael
    Briggs, Andrew
    Sukhtankar, Sunil
    Farrell, Robert
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (19) : 5652 - 5656
  • [32] Development of the first model of a phosphorylated, ATP/Mg2+-containing B-Raf monomer by molecular dynamics simulations: a tool for structure-based design
    Previtali, Viola
    Trujillo, Cristina
    Boisson, Jean-Charles
    Khartabil, Hassan
    Henon, Eric
    Rozas, Isabel
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2017, 19 (46) : 31177 - 31185
  • [33] Discovery of Novel HCV NS5B polymerase inhibitor, 2-(3,4-dimethyl-5,5-dioxidobenzo[e]pyrazolo[4,3-c][1,2]thiazin-2(4H)-yl)-N-(2-fluorobenzyl)acetamide via molecular docking and experimental approach
    Khalid, Hina
    Shahid, Sana
    Tariq, Somayya
    Ijaz, Bushra
    Ashfaq, Usman Ali
    Ahmad, Matloob
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2021, 48 (12) : 1653 - 1661